cohort
blood
product
recipi
transfusionacquir
hiv
tahiv
infect
follow
prospect
australian
red
cross
blood
servic
hiv
lookback
team
sinc
individu
cohort
remain
asymptomat
year
sinc
infect
without
antiretrovir
therapi
maintain
plasma
hiv
rna
level
detect
level
stabl
cell
count
thu
retain
elit
nonprogressor
statu
earli
natur
histori
studi
cohort
suggest
tahiv
infect
may
result
shorter
time
aid
sexuallyacquir
sa
hiv
infect
observ
increas
rate
diseas
progress
tahiv
may
due
higher
inocul
volum
blood
product
compar
much
smaller
blood
genit
fluid
exchang
involv
sahiv
infect
well
known
immunomodulatori
effect
transfus
immun
function
age
also
independ
predictor
increas
rate
hiv
diseas
progress
bia
toward
age
popul
requir
transfus
part
composit
disadvantag
transfus
rout
hiv
infect
addit
hiv
infect
surviv
may
influenc
underli
medic
caus
transfus
yet
despit
disadvantag
previous
observ
high
frequenc
nonprogress
tahiv
cohort
year
infect
earli
studi
cohort
tahiv
patient
led
identif
sydney
blood
bank
cohort
sbbc
longterm
survivor
attenu
nefdelet
strain
transmit
singl
donor
result
slow
nonprogress
individu
howev
prolong
infect
sbbc
member
maintain
nonprogress
diseas
although
hla
type
explain
nonprogress
group
observ
differ
cell
respons
associ
hladepend
epitop
recognit
detect
increas
preserv
helper
cell
respons
nonprogressor
cohort
addit
well
describ
host
genet
factor
may
prolong
nonprogress
recent
studi
suggest
influenc
innat
immun
mechan
includ
polymorph
decreas
tlr
function
therebi
reduc
immun
activ
upon
exposur
infect
diseas
polymorph
rr
strongli
associ
progress
hiv
diseas
result
impair
elimin
hiv
immun
complex
host
genet
factor
may
predispos
individu
delay
diseas
progress
substanti
evid
antivir
cell
respons
requir
sustain
nonprogressor
statu
earlier
studi
demonstr
import
role
gagspecif
ctl
delay
diseas
progress
nonprogressor
control
viraemia
absenc
antivir
therapi
also
strong
cell
prolif
respons
gag
protein
importantli
gag
ctl
effici
kill
hivinfect
cell
therefor
protect
control
viraemia
must
also
accompani
cell
prolif
respons
appropri
cell
help
also
requir
achiev
matur
display
effector
phenotyp
ctl
associ
effect
virolog
control
determin
host
genet
immun
factor
combin
contribut
prolong
nonprogress
tahiv
cohort
report
current
statu
elit
nonprogressor
antiretrovir
therapi
art
examin
factor
influenc
diseas
former
nonprogressor
therapi
deceas
analys
potenti
mechan
influenc
nonprogress
cohort
year
prospect
studi
began
ltnp
identifi
nsw
tahiv
cohort
accord
origin
guidelin
classifi
ltnp
least
year
infect
stabl
cell
count
histori
art
subsequ
loss
ltnp
statu
defin
follow
event
consist
declin
cell
count
commenc
art
viral
load
test
becam
routin
plasma
viraemia
copiesml
elit
nonprogressor
also
defin
viraemia
suppress
copiesml
addit
criteria
diseas
progress
defin
cell
count
andor
plasma
viraemia
copiesml
two
nonprogressor
group
studi
includ
sbbc
consist
recipi
hivinfect
blood
common
donor
cohort
consist
recipi
infect
blood
differ
donor
clinic
data
ltnp
collect
prospect
sinc
late
cell
count
viral
load
test
perform
part
routin
clinic
care
blood
sampl
clinic
histori
provid
inform
consent
grant
accord
guidelin
arcb
institut
human
research
ethic
committe
antihiv
cell
function
assay
perform
previous
describ
briefli
prolif
respons
determin
day
cultur
pbmc
cellswel
rpmi
medium
pool
human
serum
round
bottom
microtitr
plate
chiron
emeryvil
ca
usa
medium
alon
control
day
prolif
respons
determin
incorpor
hour
cultur
follow
cell
harvest
read
liquid
scintil
counter
result
express
stimul
index
si
mean
count
antigen
wellsmean
count
control
well
si
consid
posit
respons
respons
cell
hiv
antigen
measur
elispot
use
precoat
elispot
kit
accord
manufactur
protocol
mabtech
mosman
australia
firstli
respons
whole
hiv
protein
determin
respons
antigen
present
autolog
b
lymphoblastoid
cell
line
infect
hour
pfucel
recombin
vaccinia
express
env
gag
pol
nef
gene
therion
biolog
cambridg
usa
e
coli
lacz
control
gag
respons
characteris
use
overlap
gag
peptid
firstli
use
matrix
peptid
pool
individu
peptid
confirm
full
gag
peptid
set
kindli
provid
nih
aid
research
refer
reagent
program
divis
aid
niaid
nih
dna
pbmc
isol
use
qiaamp
dna
mini
kit
qiagen
valencia
ca
accord
manufactur
protocol
nest
polymeras
chain
reaction
pcr
use
amplifi
kb
hiv
gag
gene
use
follow
primer
outer
sens
outer
antisens
inner
sens
inner
antisens
primari
secondari
pcr
reaction
contain
unit
taq
dna
polymeras
promega
madison
wi
pcr
buffer
promega
mm
tri
hcl
mm
kcl
triton
mm
nm
dntp
nm
primer
total
volum
ul
thermocycl
condit
follow
min
cycl
min
final
singl
cycl
min
rna
isol
plasma
use
qiaamp
viral
rna
mini
kit
qiagen
valencia
ca
accord
manufactur
protocol
gag
gene
amplifi
use
qiagen
onestep
rtpcr
kit
use
outer
primer
pair
mention
second
round
pcr
reaction
perform
use
inner
primer
pair
condit
pcr
product
purifi
use
millipor
pcr
purif
plate
millipor
billerica
usa
sequenc
abi
prism
bigdy
termin
readi
reaction
cycl
sequenc
kit
appli
biosystem
foster
citi
ca
usa
abi
autom
sequenc
multipl
sequenc
deriv
patient
analys
use
sequench
softwar
gene
code
corp
ann
arbor
mi
usa
chromatogram
deriv
forward
revers
primer
align
refer
strain
method
hla
chemokin
receptor
polymorph
tolllik
receptor
tlr
polymorph
describ
elsewher
fisher
exact
test
use
associ
genet
immun
factor
viraemia
nonprogressor
statu
report
tahiv
case
state
nsw
australia
cohort
remain
asymptomat
year
infect
report
remain
nonprogressor
year
infect
infect
treatment
histori
subject
summaris
addit
file
individu
surviv
advantag
least
one
host
genet
polymorph
associ
slow
progress
infect
sbbc
nefdefect
strain
combin
least
one
host
viral
factor
favour
slow
progress
act
opposit
surviv
advantag
former
nonprogressor
polymorph
rr
genotyp
absent
current
ltnp
effect
rr
genotyp
promot
diseas
progress
signific
small
studi
individu
balanc
compet
surviv
factor
along
antivir
immun
respons
enabl
nonprogress
diseas
cours
establish
earli
infect
loss
nonprogressor
statu
base
increas
viraemia
andor
decreas
count
initi
art
individu
addit
file
patient
lost
ltnp
statu
due
gradual
increas
viraemia
die
unrel
caus
substanti
cell
loss
observ
anoth
two
elderli
individu
sbbc
member
low
detect
viraemia
die
lose
nonprogressor
statu
host
viral
genet
factor
may
play
role
delay
diseas
progress
second
decad
infect
individu
studi
also
demonstr
import
host
immun
respons
sustain
nonprogress
diseas
cours
beyond
second
decad
infect
immun
statu
activ
hivspecif
cell
prolifer
cell
respons
shown
current
nonprogressor
figur
compar
lost
nonprogressor
statu
die
figur
antivir
ctl
respons
variabl
second
decad
hiv
infect
alway
correl
viremia
member
cohort
strong
gagspecif
ctl
detect
cohort
nonprogressor
art
predomin
ctl
respons
sbbc
member
pol
antigen
ctl
appear
equal
effect
contain
viral
replic
whether
gagspecif
demonstr
earlier
time
point
polspecif
figur
main
factor
differenti
ltnp
lost
nonprogressor
statu
low
undetect
hiv
viraemia
copiesml
p
low
viraemia
associ
detect
prolif
respons
p
loss
nonprogressor
statu
strongli
associ
undetect
declin
respons
p
combin
detect
prolif
respons
strong
pbmc
gag
ctl
respons
associ
low
copiesml
undetect
viraemia
p
illustr
import
combin
gagspecif
cell
respons
time
low
viraemia
intermitt
detect
earlier
time
point
sharp
increas
gag
ctl
tempor
associ
control
transient
viraemia
year
post
infect
howev
gag
ctl
later
fail
contain
viraemia
beyond
approxim
year
coincid
weaken
prolif
respons
gradual
becam
neg
similar
correl
anti
viral
immun
respons
spike
viral
replic
demonstr
sbbc
member
shown
detail
figur
cours
month
respons
increas
viraemia
peak
copiesml
prolif
respons
increas
along
substanti
expans
polspecif
ctl
precursor
effector
ctl
popul
durabl
immun
control
individu
determin
die
soon
caus
unrel
hiv
diseas
age
declin
gagspecif
cell
respons
preced
detect
viraemia
demonstr
declin
year
follow
period
low
detect
viraemia
copiesml
year
rebound
gagspecif
cell
respons
coincid
first
detect
viraemia
year
cell
respons
may
help
contain
viraemia
low
level
follow
two
year
sharp
increas
viral
rna
year
figur
coincid
declin
gagspecif
cell
respons
wherea
polspecif
ctl
increas
respons
rise
viraemia
exampl
demonstr
influenc
conserv
gagspecif
respons
particularli
helper
cell
respons
reduc
viral
replic
delay
diseas
progress
declin
respons
preced
detect
viraemia
suffici
patient
specimen
avail
allow
critic
observ
made
other
progress
determin
strong
gag
ctl
may
contain
viral
replic
fail
other
map
breadth
gag
ctl
respons
time
patient
least
moder
clt
respons
whole
gag
antigen
pool
overlap
gag
peptid
use
test
sequenti
pbmc
span
studi
period
elispot
composit
peptid
pool
exampl
respons
shown
figur
indic
relev
hlaspecif
epitop
contain
peptid
intersect
posit
pool
figur
demonstr
broad
strong
respons
pbmc
multipl
immunodomin
epitop
contrast
figur
restrict
respons
two
immunodomin
epitop
sequenti
analysi
reveal
rel
high
stabil
repertoir
gag
respons
past
year
subject
addit
file
relev
epitop
intersect
posit
peptid
pool
confirm
use
individu
peptid
figur
data
demonstr
retent
broadli
reactiv
gag
ctl
associ
ongo
nonprogress
restrict
toward
narrow
ctl
specif
observ
patient
eventu
lost
control
viraemia
possibl
sbbc
nonprogressor
respons
sever
gag
epitop
although
gag
respons
moder
weak
need
view
context
pol
ctl
domin
sbbc
strong
restrict
gag
respons
also
seen
gag
respons
like
secondari
control
viraemia
suggest
kinet
pol
ctl
respons
spike
viraemia
figur
pol
ctl
recognit
confirm
subsequ
analysi
respons
peptid
pool
deriv
full
set
pol
overlap
peptid
moder
strong
respons
multipl
pool
contain
epitop
revers
transcriptas
protein
detect
sbbc
member
weakli
data
shown
also
respond
strongli
integras
peptid
strong
narrow
ctl
respons
may
eventu
fail
control
viral
replic
restrict
recognit
one
two
gag
epitop
appear
suffici
contain
viraemia
mani
year
recent
viral
load
result
figur
suggest
immun
escap
ctl
may
occur
recent
similarli
predomin
respons
immunodomin
epitop
figur
may
contain
earlier
spike
increas
viraemia
ultim
fail
contain
increas
viral
replic
later
year
figur
determin
immunodomin
ctl
initi
contribut
reduc
viral
replic
sequenc
plasma
pbmc
deriv
viru
span
period
sign
diseas
progress
carri
determin
viral
escap
mutant
emerg
region
gag
figur
except
one
sampl
well
characteris
escap
mutant
detect
earliest
time
point
escap
mutant
detect
henc
caus
loss
control
viraemia
detect
latest
time
point
viraemia
first
increas
copiesml
suggest
immun
escap
gag
epitop
major
caus
diseas
progress
long
term
infect
individu
sole
common
factor
declin
prolif
respons
nonprogressor
consid
repres
tail
end
distribut
curv
rate
diseas
progress
although
elit
nonprogressor
extend
curv
even
diseas
progress
may
inevit
rare
group
individu
recent
analys
sbbc
may
support
suggest
howev
death
caus
prevent
establish
definit
proof
diseas
progress
individu
two
sbbc
subject
consent
prospect
analysi
die
unrel
caus
sole
sbbc
recipi
therapi
sinc
die
nonhiv
caus
two
elderli
subject
also
die
nonhiv
caus
control
viraemia
low
level
along
normal
cell
count
suggest
evid
loss
ltnp
statu
death
leav
three
elit
nonprogressor
sbbc
describ
studi
one
also
advanc
age
one
elderli
cohort
ltnp
wildtyp
hiv
infect
also
die
recent
nonhiv
caus
age
may
opportun
determin
factor
involv
diseas
progress
two
cohort
nonprogressor
low
detect
viraemia
recent
invers
cell
ratio
evid
chang
hivinduc
immun
activ
base
declin
prolif
respons
preced
recent
increas
viraemia
like
togeth
signifi
transitionari
stage
toward
diseas
progress
prolif
respons
singl
immun
paramet
consist
defin
control
viraemia
nonprogress
prolif
respons
may
also
specif
protect
suggest
studi
show
respons
pol
antigen
associ
increas
viraemia
wherea
protect
associ
alway
found
respons
gag
antigen
hivspecif
prolif
respons
may
also
promot
ctl
prolifer
support
respons
spike
viraemia
patient
hivspecif
memori
cell
pool
increas
maintain
throughout
period
prolifer
ctl
precursor
assay
measur
prolifer
antigenspecif
memori
cell
wherea
effector
ctl
elispotposit
cell
peak
declin
viraemia
declin
data
suggest
effect
helper
cell
function
involv
prolifer
follow
matur
effector
costimulatori
cell
provid
help
lymphocyt
function
thu
antigenspecif
cell
prolifer
may
directli
associ
prolifer
epitop
correspond
antigen
also
possibl
loss
protect
hivspecif
prolifer
may
mediat
common
immunolog
defect
distinguish
featur
slow
nonprogressor
subject
studi
predomin
gag
ctl
sbbc
nonprogressor
except
poldomin
ctl
respons
observ
unexpect
consid
extens
publish
role
gag
ctl
control
viraemia
also
peculiar
sbbc
member
strongest
ctl
respons
detect
detect
viraemia
weaker
subject
undetect
viraemia
nonattenu
hivinfect
nonprogressor
strong
immunodomin
ctl
combin
detect
prolif
respons
appear
contribut
viraemia
remain
copiesml
year
infect
patient
individu
strongest
ctl
respons
ctl
increas
viraemia
increas
patient
prolif
respons
gag
declin
given
predomin
ctl
respons
subject
direct
immunodomin
hla
restrict
epitop
immun
escap
sequenc
detect
epitop
like
declin
prolif
respons
key
event
contribut
failur
ctl
control
viraemia
understood
ctl
much
reduc
function
effici
contain
viraemia
absenc
helper
cell
respons
anoth
studi
hla
posit
individu
found
associ
diseas
progress
strength
ctl
respons
emerg
viral
escap
mutant
epitop
found
viral
replic
fit
influenc
diseas
cours
contribut
prolif
respons
investig
studi
neutralis
antibodi
nab
respons
anoth
immun
mechan
may
contribut
long
term
control
viraemia
recent
analys
viral
replic
fit
strength
nab
respons
confirm
nab
titr
longterm
infect
subject
invers
proport
viral
load
howev
nab
titr
sbbc
member
compar
weaker
parallel
ctl
respons
highest
detect
viraemia
presenc
strong
nab
prevent
sbbc
member
develop
sign
diseas
progress
henc
suggest
broad
nab
might
gener
due
crippl
infect
prevent
diseas
progress
particularli
absenc
antivir
helper
cell
respons
key
factor
sustain
nonprogress
diseas
cours
initi
declin
protect
immun
mani
year
nonprogress
diseas
cours
could
chang
viral
pathogen
overcom
delic
balanc
host
viru
could
progress
weaken
cell
respons
slow
viru
turnov
gradual
allow
viru
escap
combin
effector
mechan
hivspecif
cellmedi
humor
immun
respons
escap
mutant
epitop
krwiilglnk
observ
condit
high
viral
load
evolutionari
drift
like
prolong
period
immun
control
presenc
prolif
respons
low
viraemia
beyond
second
decad
hiv
infect
diseas
progress
one
sbbc
member
sbbc
infect
donor
associ
emerg
diverg
strain
preced
viral
load
increas
subsequ
chang
immun
respons
also
individu
lack
protect
prolif
respons
detect
viraemia
viral
diverg
occur
provid
evid
effect
immun
control
viral
replic
level
put
threshold
may
prevent
emerg
escap
mutant
fitter
variant
therefor
common
factor
observ
declin
lack
prolif
respons
suggest
lack
helper
cell
respons
may
result
reduc
capac
contain
viral
replic
immun
effector
respons
includ
ctl
independ
presenc
viral
escap
mutant
studi
demonstr
host
viral
genet
factor
contribut
delay
diseas
progress
singl
immunolog
factor
function
defin
nonprogress
gagspecif
cell
prolifer
mainten
respons
requir
detect
viral
replic
antigen
stimul
detect
cell
prolifer
defin
immunocompet
recal
respons
viral
antigen
spike
viral
replic
detect
individu
cell
like
provid
cell
help
maintain
function
antivir
effector
respons
cell
includ
noncytolyt
antivir
mechan
may
also
provid
cell
help
effici
gener
nab
hivspecif
b
cell
demonstr
declin
protect
respons
slow
progressor
either
preced
coincid
classic
sign
diseas
progress
author
declar
compet
interest
wbd
wrote
manuscript
direct
immunolog
experiment
work
bw
nk
provid
sequenc
data
jcl
provid
patient
clinic
detail
ffi
provid
host
genet
data
jjz
adk
assist
analysi
cell
immun
data
dm
prg
provid
commentari
neutralis
antibodi
viral
evolut
help
edit
manuscript
afg
jss
contribut
design
ltnp
studi
